Idiopathic pulmonary arterial hypertension is a rare condition associated with significant maternal mortality. We report the management of a 37-year-old multigravida with severe disease using epoprostenol, a multidisciplinary approach, and a planned delivery. Although the patient survived the pregnancy, her pulmonary function significantly worsened. Epoprostenol, a pulmonary vasodilator, should be considered when indicated during pregnancy. Neither fetal nor neonatal harm was identified.
Introduction
Idiopathic pulmonary arterial hypertension (PAH; sustained mean pulmonary artery (PA) pressures greater than 25 mm Hg) is a rare condition with maternal mortality reported to be 35-50%. [1] [2] [3] Neonatal outcomes reflect the gestational age at delivery. 1,2,4 -6 Intravenous epoprostenol improves the functional status and survival in non-pregnant patients. [7] [8] [9] Growing evidence supports the use of epoprostenol in pregnancy. 4, 5 We report a method of modern management for a pregnant woman with severe PAH presenting in the second trimester.
Case presentation
A 37-year-old G2 P0101 woman with known PAH presented with baseline New York Heart Association or World Health Organization functional class III disease. 10 Previously lost to follow-up, she presented to the Department of Cardiology with a 3-week history of worsening dyspnea and exercise intolerance. She had not established prenatal care and was evaluated at 23 weeks gestation by ultrasound. She had a 5-year history of vasoreactive PAH and the condition was managed with an extended release of nifedipine 90 mg daily. At the time of presentation, right heart catheterization revealed an elevated PA pressure of 85/34, an elevated mean PA pressure of 53 mm Hg and a normal cardiac output (CO; 7.8 l min
À1
; normal at 24 weeks gestation, 7.21 l min À1 ). Her obstetric history was significant for eclampsia at 36 weeks gestation and emergent cesarean delivery (CD) 21 years prior to the current pregnancy.
During her initial evaluation, the patient was counseled about the high maternal mortality among pregnant women with PAH. She was informed of the options and counseled about the risks of prematurity, especially at its extreme. The patient elected to continue the pregnancy. A multi-disciplinary team consisting of Cardiology, Maternal Fetal Medicine, Anesthesiology and Neonatology was assembled. A multi-disciplinary conference was held to develop a consensus. She was hospitalized on the telemetry unit for the duration of her pregnancy, out of concern for acute decompensation.
Continuous epoprostenol infusion was initiated at 2 ng kg À1 min À1 on admission to the hospital. The dose was titrated to address increasing dyspnea and hypoxia to a maximum of 12 ng kg À1 min À1 . Nifedipine was continued at the previous dose. Her hemodynamic status was followed with serial right-heart catheterization ( Table 1) . Echocardiography was performed between catheterizations for additional, non-invasive, surveillance.
She received therapeutic anticoagulation with enoxaparin, as both pregnancy and pulmonary hypertension are hypercoagulable states. Enhanced fetal surveillance consisted of twice weekly Doppler studies and biophysical profiles ( Figure 1 ). Betamethasone was given to accelerate fetal lung maturity in anticipation of preterm delivery.
At 31 weeks gestation, the patient became increasingly dyspneic. Symptoms were not improved with increasing epoprostenol. Heart catheterization showed a decrease in CO (5.6 l min À1 ; normal at 32 weeks, 7.33 l min À1 ). These findings were consistent with decompensation and the decision was made to proceed with delivery.
In the main operating room (OR), maternal status was monitored by an arterial line, a Swan-Ganz catheter (Edwards Lifesciences, LLC., Irvine, CA, USA), and transesophageal echocardiography. Preparations were made for possible extracorporeal membrane oxygenation with a team on standby. An epidural catheter was placed for postoperative pain control. Inhaled nitric oxide was started before the induction of general anesthesia for intraoperative management of PA pressures. A repeat CD and bilateral tubal ligation were performed at 31 weeks and 4 days gestation. An 1820-g neonate was delivered with 1-and 5-min Apgar scores of 7 and 7, respectively. Following delivery of the placenta, the patient became hypotensive and received phenylephrine with appropriate response. Phenylephrine was discontinued intra-operatively and otherwise the procedure occurred without complication.
The patient was extubated on the day of surgery and received postoperative care in the intensive care unit. On postoperative day 2, she was weaned from nitric oxide. Sildenafil and ambrosentan were initiated. Intravenous epoprostenol and oral nifedipine were continued.
She was monitored on telemetry from postoperative day 6 until discharge. She was discharged home on sildenafil, ambrosentan and intravenous epoprostenol. Although medically cleared for discharge on postoperative day 7, her hospitalization was prolonged until postoperative day 33 owing to difficulty in arranging for home-health to manage continuous epoprostenol infusion at home. Her postpartum course was overall uncomplicated. She was seen in the Cardiology clinic approximately 1 month after discharge and was found to be stable with NYHA or WHO functional class III disease.
The neonate received surfactant for respiratory distress and indomethacin for a patent ductus arteriosus. The neonatal course was otherwise without major complication. The infant was discharged on day of life 41.
Discussion
The normal hemodynamic changes of pregnancy and the puerperium pose an especially high threat to the gravida with PAH. 2 In normal pregnancy, CO increased and systemic vascular resistance decreased, with very little change in PA pressure, pulmonary capillary wedge pressure and central venous pressure. 11, 12 Endothelial dysfunction with dysregulation of vasodilation and vasoconstriction, in combination with loss of the antithrombotic and prothrombotic equilibrium, are hallmarks of PAH. 7 The pulmonary vasculature in PAH is ill suited to adjust to the increases in blood volume during pregnancy and hemodynamic changes after delivery.
Advanced therapies for PAH include prostanoids (for example, epoprostenol), phosphodiesterase type 5 inhibitors (for example, ); PAP, pulmonary arterial pressure (mm Hg) in the format of systolic/diastolic (mean); RASP, right atrial systolic pressure; XwYd, gestational age in the format of X weeks and Y days. 8, 13 Moreover, the addition of prostanoids to oral therapy confers a benefit to persons with worsening status on oral monotherapy.
14 Continuous epoprostenol therapy is administered via an indwelling central venous catheter and has risks of infection, sepsis and thrombosis. In addition, epoprostenol has nuisance side effects (for example, diarrhea and jaw pain). 8 Experience with sildenafil in pregnancy is limited. 5, 15 Endothelin receptor agonists are class X medications and are contraindicated in pregnancy. 5, 16 Pregnancy is generally contraindicated in women with PAH. 15 Historically, maternal mortality rates of 30-50% were reported. 1, 3 Prostanoids were not available for these patients. A decrease in maternal mortality has been noted over the last three decades. 15 Current published experience with prostanoids in pregnancy is limited. 4, 5, 15, 17, 18 Early initiation of treatment before acute decompensation decreases mortality and improves the outcomes. 15 In non-pregnant patients a significant survival advantage is seen with long-term intravenous epoprostenol, which seems to justify the cost. 13, 19 Oral non-prostanoid therapies are most cost effective; however, for patients requiring the addition of prostanoids, epoprostenol has the greatest impact on clinical markers of functional status with no difference noted in cost-savings. 20 Decisions regarding the choice of anesthesia should be individualized. Our multi-disciplinary team opted for general anesthesia for the use of inhaled nitric oxide as an additional mechanism for control of PA pressure and to facilitate the use of ECMO if necessary. An epidural was placed to allow for postoperative pain control and sympathetic blockade as needed. Postoperative increases in peripheral vascular resistance occur and may contribute to post-partum mortality. 21 Although there may be less alteration to hemodynamic parameters with regional anesthesia, good outcomes have been reported with both regional and general anesthesia [1] [2] [3] [4] [22] [23] [24] Little has been written about the effects of epoprostenol on the intrauterine environment. In our case, intensive fetal surveillance during intravenous epoprostenol therapy failed to show fetal harm. Epoprostenol causes vasodilation of the ductus arteriosus, 25 but given its short half-life, 19 would be unlikely to have neonatal effects.
An improved understanding of the interaction between PAH and pregnancy, along with advances in treatment, may have decreased maternal mortality, but morbidity remains high. Although our patient survived pregnancy, her functional status worsened. The extent to which pregnancy hastened the progression of her disease is unclear.
Planned delivery affords the benefit of coordinated multidisciplinary sub-specialty care in an idealized environment. Our team, including obstetricians, cardiologists and neonatologists, agreed that worsening maternal status (as evident by the increase in dyspnea accompanied by a decrease in CO) was greater than the risks of prematurity at 31 completed weeks of gestation. Maternal status and history, fetal status, parity and Bishop score should be used to guide the specific mode and timing of delivery. The modern-day management of a gravida with PAH requires a skilled multidisciplinary team, use of advanced PAH therapies and a planned, controlled delivery.
